This cohort study examines data from 3 single-center observational cohorts to test the capabilities of a commercially available plasma phosphorylated tau 217 immunoassay to identify Alzheimer disease pathophysiology. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.